LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 11 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 1. - Dataset (ID:20248)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MCF7 | A443654 | 3.33 | uM | LJP6 | 72 | hr | 1235 | 584 | 4056 | 0.1442 | -0.3553 |
| MDA-MB-231 | A443654 | 1.11 | uM | LJP6 | 72 | hr | 868 | 633 | 3556 | 0.1787 | -0.1449 |
| MCF7 | A443654 | 1.11 | uM | LJP6 | 72 | hr | 1235 | 790 | 4056 | 0.1947 | -0.2296 |
| MCF7 | A443654 | 0.12 | uM | LJP6 | 72 | hr | 1235 | 982 | 4056 | 0.2422 | -0.1252 |
| MDA-MB-231 | A443654 | 10 | uM | LJP6 | 72 | hr | 868 | 661 | 3556 | 0.1860 | -0.1254 |
| SK-BR-3 | A443654 | 0.12 | uM | LJP6 | 72 | hr | 1476 | 1235 | 3643 | 0.3408 | -0.1267 |
| MCF7 | A443654 | 0.37 | uM | LJP6 | 72 | hr | 1235 | 838 | 4056 | 0.2067 | -0.2026 |
| MDA-MB-231 | A443654 | 3.33 | uM | LJP6 | 72 | hr | 868 | 572 | 3556 | 0.1608 | -0.1881 |
| MCF7 | A443654 | 0.04 | uM | LJP6 | 72 | hr | 1235 | 1024 | 4056 | 0.2524 | -0.1040 |
| Hs 578T | A443654 | 1.11 | uM | LJP6 | 72 | hr | 929 | 719 | 3216 | 0.2237 | -0.1339 |
| Hs 578T | A443654 | 3.33 | uM | LJP6 | 72 | hr | 929 | 638 | 3216 | 0.1983 | -0.1895 |
| MDA-MB-231 | Afatinib | 1.11 | uM | LJP6 | 72 | hr | 868 | 2626 | 3556 | 0.7383 | 0.7222 |
| BT-20 | Afatinib | 1.11 | uM | LJP6 | 72 | hr | 1657 | 5087 | 5383 | 0.9459 | 0.9359 |
| MDA-MB-231 | Afatinib | 3.33 | uM | LJP6 | 72 | hr | 868 | 2182 | 3556 | 0.6146 | 0.5740 |
| MDA-MB-231 | Afatinib | 10 | uM | LJP6 | 72 | hr | 868 | 732 | 3556 | 0.2054 | -0.0831 |
| BT-20 | Afatinib | 3.33 | uM | LJP6 | 72 | hr | 1657 | 4854 | 5383 | 0.9034 | 0.8832 |
| MDA-MB-231 | Afatinib | 0.04 | uM | LJP6 | 72 | hr | 868 | 2549 | 3556 | 0.7165 | 0.6971 |
| BT-20 | Afatinib | 0.12 | uM | LJP6 | 72 | hr | 1657 | 4514 | 5383 | 0.8387 | 0.8034 |
| BT-20 | Afatinib | 0.37 | uM | LJP6 | 72 | hr | 1657 | 4690 | 5383 | 0.8712 | 0.8428 |
| BT-20 | Afatinib | 10 | uM | LJP6 | 72 | hr | 1657 | 1569 | 5383 | 0.2917 | -0.0317 |
| SK-BR-3 | Afatinib | 3.33 | uM | LJP6 | 72 | hr | 1476 | 1484 | 3643 | 0.4075 | 0.0023 |
| MCF7 | Afatinib | 10 | uM | LJP6 | 72 | hr | 1235 | 664 | 4056 | 0.1637 | -0.3041 |
| SK-BR-3 | Afatinib | 10 | uM | LJP6 | 72 | hr | 1476 | 1228 | 3643 | 0.3371 | -0.1337 |
| MCF7 | Afatinib | 0.04 | uM | LJP6 | 72 | hr | 1235 | 2830 | 4056 | 0.6983 | 0.6221 |
| MCF7 | Afatinib | 0.12 | uM | LJP6 | 72 | hr | 1235 | 2890 | 4056 | 0.7125 | 0.6409 |